US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sunshine Biopharma Inc.

1.45

+0.05003.57%

Post-market: 1.450.00000.00%19:21 EDT

Volume:80.20K

Turnover:114.22K

Market Cap:6.61M

PE:-0.57

High:1.48

Open:1.39

Low:1.37

Close:1.40

52wk High:3.90

52wk Low:1.17

Shares:4.56M

Float Shares:4.55M

Volume Ratio:2.21

T/O Rate:1.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5393

EPS(LYR):-7.3162

ROE:-25.65%

ROA:-11.08%

PB:0.26

PE(LYR):-0.20

Loading ...

Overview Company News Filings

Sunshine Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

Sunshine Biopharma Inc expected to post a loss of 11 cents a share - Earnings Preview

Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada

Sunshine Biopharma Inc. Reports 18% Revenue Increase in Q1 2025, Net Loss Narrows to $1.18 Million

Sunshine Biopharma Q1 EPS $(0.44) Up From $(2.00) YoY, Sales $8.90M Up From $7.54M YoY

Sunshine Biopharma Unit Rolls Out Afinitor Alternative Everolimus in Canadian Market

MT Newswires Live

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

ACCESS Newswire

Sunshine Biopharma Closes $2.5 Million Direct Offering

MT Newswires Live

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

ACCESS Newswire

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Wall Street Awaits Trump's Tariff Plans as US Equity Futures Drop Pre-Bell

MT Newswires Live

Sunshine Biopharma Completes Additional Studies of mRNA Therapy for Liver Cancer; Shares Up Pre-Bell

MT Newswires Live

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

ACCESS Newswire

Top Premarket Gainers

MT Newswires Live

Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

ACCESS Newswire

Sunshine Biopharma Inc expected to post earnings of 11 cents a share - Earnings Preview

Sunshine Biopharma signs agreement for rights to market two generic antibiotics

Sunshine Biopharma Inc expected to post earnings of 11 cents a share - Earnings Preview

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SBFM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SBFM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBFM\",,,,,undefined,":{"symbol":"SBFM","market":"US","secType":"STK","nameCN":"Sunshine Biopharma Inc.","latestPrice":1.45,"timestamp":1756238400000,"preClose":1.4,"halted":0,"volume":80202,"hourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.45,"latestTime":"19:21 EDT","volume":155,"amount":229.00501350000002,"timestamp":1756250489313},"delay":0,"floatShares":4554219,"shares":4555945,"eps":-2.539277,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"08-26 19:53:06 EDT","open":1.39,"high":1.48,"low":1.37,"amount":114220.8332088,"amplitude":0.078571,"askPrice":1.51,"askSize":1,"bidPrice":1.33,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.539277,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1756252800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.4,"preHourTrading":{"tag":"盘前","latestPrice":1.4,"preClose":1.42,"latestTime":"08:46 EDT","volume":1,"amount":1.4,"timestamp":1756212365981},"postHourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.45,"latestTime":"19:21 EDT","volume":155,"amount":229.00501350000002,"timestamp":1756250489313},"volumeRatio":2.207342},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBFM\",,,,,undefined,":{"symbol":"SBFM","floatShares":4554219,"roa":"-11.08%","roe":"-25.65%","lyrEps":-7.316171,"volumeRatio":2.207342,"shares":4555945,"dividePrice":0,"high":1.48,"amplitude":0.078571,"preClose":1.4,"low":1.37,"week52Low":1.1693,"pbRate":"0.26","psRate":"0.18","week52High":3.9,"institutionHeld":0,"latestPrice":1.45,"committee":0.99005,"eps":-2.539277,"divideRate":0,"volume":80202,"delay":0,"ttmEps":-2.539277,"open":1.39,"prevYearClose":3,"prevWeekClose":1.4,"prevMonthClose":1.44,"prevQuarterClose":1.44,"fiveDayClose":1.42,"twentyDayClose":1.51,"sixtyDayClose":1.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBFM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"SBFM","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.39},{"market":"US","date":"2025-04-01","symbol":"SBFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743480000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-05","symbol":"SBFM","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730782800000,"reportTimeType":"post","actualEps":-0.94},{"market":"US","date":"2024-08-16","symbol":"SBFM","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723780800000,"reportTimeType":"post","actualEps":-9.94},{"market":"US","date":"2024-08-08","symbol":"SBFM","defaultRemindTime":1723123800000,"type":"split","dateTimestamp":1723089600000,"forFactor":20,"toFactor":1,"ratio":20}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBFM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBFM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1691640000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SBFM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SBFM","date":"2025-08-25","current":-1.011369,"percent":0.529762,"low":-6.998439,"twenty":-1.816289,"median":-1.040889,"eighty":-0.404918,"high":-0.00205,"avg":-1.322346,"sd":1.195126,"marketCap":6378323},"quantilePoints":[{"date":"2022-02-18","current":-0.00205,"twenty":-0.002132,"median":-0.002055,"eighty":-0.002052,"marketCap":29086},{"date":"2022-02-25","current":-0.570765,"twenty":-0.648304,"median":-0.570765,"eighty":-0.002081,"marketCap":8097652},{"date":"2022-03-04","current":-0.551815,"twenty":-0.628759,"median":-0.547084,"eighty":-0.10265,"marketCap":7828789},{"date":"2022-03-11","current":-0.939661,"twenty":-0.648304,"median":-0.548661,"eighty":-0.483074,"marketCap":13331310},{"date":"2022-03-18","current":-1.446928,"twenty":-0.935877,"median":-0.56129,"eighty":-0.499471,"marketCap":20528089},{"date":"2022-03-25","current":-1.668294,"twenty":-1.547902,"median":-0.646411,"eighty":-0.504516,"marketCap":20747653},{"date":"2022-03-30","current":-1.438975,"twenty":-1.549536,"median":-0.687403,"eighty":-0.528165,"marketCap":17895742},{"date":"2022-04-08","current":-5.532316,"twenty":-1.563447,"median":-0.930201,"eighty":-0.544877,"marketCap":68802357},{"date":"2022-04-14","current":-2.728894,"twenty":-1.661414,"median":-1.246939,"eighty":-0.546769,"marketCap":33937743},{"date":"2022-04-22","current":-1.960676,"twenty":-2.280575,"median":-1.433243,"eighty":-0.549923,"marketCap":24383840},{"date":"2022-04-29","current":-1.725624,"twenty":-2.273696,"median":-1.497415,"eighty":-0.551815,"marketCap":21460631},{"date":"2022-05-06","current":-2.007547,"twenty":-2.273696,"median":-1.561537,"eighty":-0.559395,"marketCap":24966754},{"date":"2022-05-13","current":-4.560355,"twenty":-2.670417,"median":-1.628163,"eighty":-0.599762,"marketCap":34145906},{"date":"2022-05-20","current":-4.009587,"twenty":-3.360667,"median":-1.725624,"eighty":-0.645781,"marketCap":30022004},{"date":"2022-05-27","current":-2.996175,"twenty":-3.49774,"median":-1.909079,"eighty":-0.6647,"marketCap":22434025},{"date":"2022-06-03","current":-2.687745,"twenty":-3.408824,"median":-1.972142,"eighty":-0.732179,"marketCap":20124640},{"date":"2022-06-10","current":-2.930083,"twenty":-3.203035,"median":-2.046154,"eighty":-0.913174,"marketCap":21939157},{"date":"2022-06-17","current":-2.752515,"twenty":-3.128359,"median":-2.187334,"eighty":-0.924526,"marketCap":20609611},{"date":"2022-07-29","current":-2.53353,"twenty":-3.084298,"median":-2.26739,"eighty":-0.932093,"marketCap":18969948},{"date":"2022-08-05","current":-4.182642,"twenty":-3.084298,"median":-2.350518,"eighty":-1.0948,"marketCap":21529620},{"date":"2022-08-19","current":-4.62292,"twenty":-3.49774,"median":-2.401346,"eighty":-1.237196,"marketCap":23795896},{"date":"2022-08-22","current":-4.292712,"twenty":-3.557362,"median":-2.423376,"eighty":-1.256681,"marketCap":22096189},{"date":"2022-08-31","current":-4.035883,"twenty":-3.969932,"median":-2.467438,"eighty":-1.299091,"marketCap":20774195},{"date":"2022-09-06","current":-3.962503,"twenty":-3.990753,"median":-2.467438,"eighty":-1.302531,"marketCap":20396482},{"date":"2022-09-16","current":-3.563685,"twenty":-3.947827,"median":-2.53353,"eighty":-1.336929,"marketCap":18343614},{"date":"2022-09-23","current":-2.788428,"twenty":-3.889123,"median":-2.571015,"eighty":-1.433243,"marketCap":14353080},{"date":"2022-09-30","current":-2.825118,"twenty":-3.815744,"median":-2.687745,"eighty":-1.438975,"marketCap":14541936},{"date":"2022-10-03","current":-2.83429,"twenty":-3.814857,"median":-2.69972,"eighty":-1.440566,"marketCap":14589150},{"date":"2022-10-21","current":-4.476161,"twenty":-3.918475,"median":-2.720295,"eighty":-1.443747,"marketCap":23040471},{"date":"2022-10-28","current":-3.868721,"twenty":-4.065235,"median":-2.752515,"eighty":-1.507512,"marketCap":19913751},{"date":"2022-11-04","current":-3.519014,"twenty":-4.020105,"median":-2.771133,"eighty":-1.550352,"marketCap":18113676},{"date":"2022-11-07","current":-6.998439,"twenty":-4.050559,"median":-2.788428,"eighty":-1.551169,"marketCap":17951060},{"date":"2022-12-09","current":-6.468361,"twenty":-4.163802,"median":-2.838125,"eighty":-1.559627,"marketCap":16591405},{"date":"2022-12-16","current":-6.006964,"twenty":-4.184557,"median":-2.84196,"eighty":-1.563447,"marketCap":15407918},{"date":"2023-04-14","current":-0.571387,"twenty":-4.175106,"median":-2.829704,"eighty":-1.442156,"marketCap":15281438},{"date":"2023-04-28","current":-0.554413,"twenty":-4.171338,"median":-2.825118,"eighty":-1.436682,"marketCap":14827467},{"date":"2023-05-12","current":-0.732285,"twenty":-4.163802,"median":-2.753837,"eighty":-1.0948,"marketCap":19925928},{"date":"2023-05-19","current":-0.572034,"twenty":-4.140239,"median":-2.731807,"eighty":-0.714332,"marketCap":15565419},{"date":"2023-05-26","current":-0.530917,"twenty":-4.11537,"median":-2.69972,"eighty":-0.591838,"marketCap":14446578},{"date":"2023-06-02","current":-0.569323,"twenty":-4.109263,"median":-2.687745,"eighty":-0.575993,"marketCap":15491650},{"date":"2023-06-09","current":-0.516865,"twenty":-4.094587,"median":-2.53353,"eighty":-0.571516,"marketCap":14064229},{"date":"2023-06-16","current":-0.501366,"twenty":-4.030624,"median":-2.467438,"eighty":-0.563332,"marketCap":13642488},{"date":"2023-06-23","current":-0.460881,"twenty":-4.009587,"median":-2.445407,"eighty":-0.551815,"marketCap":12540859},{"date":"2023-06-30","current":-0.438831,"twenty":-3.97192,"median":-2.379315,"eighty":-0.548871,"marketCap":11940865},{"date":"2023-07-07","current":-0.442717,"twenty":-3.918475,"median":-2.310387,"eighty":-0.543244,"marketCap":12046602},{"date":"2023-07-14","current":-0.469014,"twenty":-3.876882,"median":-2.187334,"eighty":-0.531587,"marketCap":12762168},{"date":"2023-07-21","current":-0.442174,"twenty":-3.856962,"median":-2.088621,"eighty":-0.514305,"marketCap":12031848},{"date":"2023-07-28","current":-0.408015,"twenty":-3.829891,"median":-1.983608,"eighty":-0.502626,"marketCap":11102349},{"date":"2023-08-04","current":-0.46079,"twenty":-3.813971,"median":-1.909079,"eighty":-0.481612,"marketCap":12538400},{"date":"2023-08-11","current":-0.469918,"twenty":-3.78794,"median":-1.725624,"eighty":-0.478123,"marketCap":12786758},{"date":"2023-08-18","current":-0.440716,"twenty":-3.743581,"median":-1.628163,"eighty":-0.469376,"marketCap":12152254},{"date":"2023-08-25","current":-0.428578,"twenty":-3.694364,"median":-1.561537,"eighty":-0.462582,"marketCap":11817552},{"date":"2023-09-01","current":-0.400473,"twenty":-3.627295,"median":-1.497415,"eighty":-0.460826,"marketCap":11042588},{"date":"2023-09-08","current":-0.373488,"twenty":-3.597848,"median":-1.436109,"eighty":-0.459073,"marketCap":10298520},{"date":"2023-10-20","current":-0.287157,"twenty":-3.581467,"median":-1.373047,"eighty":-0.456181,"marketCap":7918029},{"date":"2023-10-27","current":-0.288968,"twenty":-3.565086,"median":-1.304251,"eighty":-0.451844,"marketCap":7967973},{"date":"2023-11-03","current":-0.251439,"twenty":-3.563685,"median":-0.939661,"eighty":-0.448186,"marketCap":6933138},{"date":"2023-11-10","current":-0.251346,"twenty":-3.524912,"median":-0.821784,"eighty":-0.444545,"marketCap":6930570},{"date":"2023-11-13","current":-0.269039,"twenty":-3.523732,"median":-0.732285,"eighty":-0.443155,"marketCap":7418457},{"date":"2023-11-24","current":-0.268406,"twenty":-3.519014,"median":-0.649565,"eighty":-0.440716,"marketCap":7184785},{"date":"2023-12-01","current":-0.277231,"twenty":-3.456981,"median":-0.601043,"eighty":-0.438831,"marketCap":7421025},{"date":"2023-12-08","current":-0.255552,"twenty":-3.242648,"median":-0.587307,"eighty":-0.434041,"marketCap":6840696},{"date":"2023-12-15","current":-0.230419,"twenty":-3.216196,"median":-0.572712,"eighty":-0.428578,"marketCap":6167925},{"date":"2023-12-22","current":-0.244616,"twenty":-3.15496,"median":-0.570765,"eighty":-0.416317,"marketCap":6547963},{"date":"2023-12-29","current":-0.274258,"twenty":-3.152218,"median":-0.566431,"eighty":-0.408308,"marketCap":7341423},{"date":"2024-01-05","current":-0.255552,"twenty":-3.151304,"median":-0.56354,"eighty":-0.406983,"marketCap":6840696},{"date":"2024-01-12","current":-0.240971,"twenty":-3.062267,"median":-0.558023,"eighty":-0.375057,"marketCap":6450386},{"date":"2024-01-19","current":-0.220346,"twenty":-3.040166,"median":-0.551815,"eighty":-0.333732,"marketCap":5898303},{"date":"2024-01-26","current":-0.240156,"twenty":-3.020968,"median":-0.548924,"eighty":-0.287518,"marketCap":6428585},{"date":"2024-02-02","current":-0.262463,"twenty":-3.000985,"median":-0.54472,"eighty":-0.278191,"marketCap":7025689},{"date":"2024-02-09","current":-0.240948,"twenty":-2.988861,"median":-0.532182,"eighty":-0.26971,"marketCap":6449790},{"date":"2024-02-16","current":-0.129173,"twenty":-2.965713,"median":-0.531475,"eighty":-0.268041,"marketCap":3457756},{"date":"2024-02-23","current":-0.122257,"twenty":-2.952965,"median":-0.517565,"eighty":-0.266975,"marketCap":3272616},{"date":"2024-03-01","current":-0.112696,"twenty":-2.945344,"median":-0.508144,"eighty":-0.25799,"marketCap":3016688},{"date":"2024-03-08","current":-0.22552,"twenty":-2.933146,"median":-0.502941,"eighty":-0.255577,"marketCap":6036788},{"date":"2024-03-15","current":-0.185766,"twenty":-2.930083,"median":-0.487991,"eighty":-0.253292,"marketCap":4972643},{"date":"2024-03-22","current":-0.222919,"twenty":-2.903653,"median":-0.484956,"eighty":-0.251383,"marketCap":5967171},{"date":"2024-03-28","current":-0.211773,"twenty":-2.864005,"median":-0.479529,"eighty":-0.249604,"marketCap":5668813},{"date":"2024-04-05","current":-2.030531,"twenty":-2.859585,"median":-0.485535,"eighty":-0.250508,"marketCap":9149663},{"date":"2024-04-12","current":-1.922383,"twenty":-2.84196,"median":-0.487991,"eighty":-0.251051,"marketCap":8662344},{"date":"2024-04-19","current":-0.732756,"twenty":-2.84196,"median":-0.502941,"eighty":-0.251346,"marketCap":3301832},{"date":"2024-04-26","current":-0.178201,"twenty":-2.83429,"median":-0.487991,"eighty":-0.251051,"marketCap":802981},{"date":"2024-05-03","current":-0.184844,"twenty":-2.825118,"median":-0.484956,"eighty":-0.245575,"marketCap":832917},{"date":"2024-05-10","current":-0.201508,"twenty":-2.788428,"median":-0.47929,"eighty":-0.244136,"marketCap":908004},{"date":"2024-05-17","current":-0.196432,"twenty":-2.753837,"median":-0.478231,"eighty":-0.240971,"marketCap":885129},{"date":"2024-05-24","current":-0.180539,"twenty":-2.753837,"median":-0.469014,"eighty":-0.23934,"marketCap":737939},{"date":"2024-05-31","current":-2.903808,"twenty":-2.826952,"median":-0.477689,"eighty":-0.239993,"marketCap":11869067},{"date":"2024-06-07","current":-2.585849,"twenty":-2.795766,"median":-0.479189,"eighty":-0.240748,"marketCap":10569437},{"date":"2024-06-14","current":-1.52954,"twenty":-2.760755,"median":-0.484377,"eighty":-0.240938,"marketCap":6251863},{"date":"2024-06-21","current":-1.48319,"twenty":-2.753837,"median":-0.485535,"eighty":-0.240962,"marketCap":6062412},{"date":"2024-06-28","current":-1.935099,"twenty":-2.753044,"median":-0.499788,"eighty":-0.241489,"marketCap":7909554},{"date":"2024-07-05","current":-1.964486,"twenty":-2.744232,"median":-0.50529,"eighty":-0.242449,"marketCap":8029671},{"date":"2024-07-12","current":-1.895758,"twenty":-2.730897,"median":-0.512599,"eighty":-0.243484,"marketCap":7748749},{"date":"2024-07-19","current":-1.683273,"twenty":-2.729277,"median":-0.524591,"eighty":-0.243849,"marketCap":6880234},{"date":"2024-07-26","current":-1.719355,"twenty":-2.722014,"median":-0.532091,"eighty":-0.24429,"marketCap":7027718},{"date":"2024-08-02","current":-1.339631,"twenty":-2.702115,"median":-0.543072,"eighty":-0.244558,"marketCap":5475627},{"date":"2024-08-09","current":-0.79324,"twenty":-2.687745,"median":-0.548661,"eighty":-0.244616,"marketCap":3242301},{"date":"2024-08-16","current":-0.892235,"twenty":-2.656047,"median":-0.551532,"eighty":-0.245,"marketCap":3283075},{"date":"2024-08-23","current":-0.931958,"twenty":-2.59944,"median":-0.554413,"eighty":-0.246151,"marketCap":3429240},{"date":"2024-08-30","current":-0.867791,"twenty":-2.564921,"median":-0.56341,"eighty":-0.247973,"marketCap":3193128},{"date":"2024-09-06","current":-0.867791,"twenty":-2.53353,"median":-0.570044,"eighty":-0.249604,"marketCap":3193128},{"date":"2024-09-13","current":-0.855568,"twenty":-2.53353,"median":-0.572034,"eighty":-0.250508,"marketCap":3148154},{"date":"2024-09-20","current":-0.96557,"twenty":-2.520312,"median":-0.586855,"eighty":-0.25111,"marketCap":3552917},{"date":"2024-09-27","current":-0.977792,"twenty":-2.467438,"median":-0.601043,"eighty":-0.251365,"marketCap":3597891},{"date":"2024-10-04","current":-0.968625,"twenty":-2.465257,"median":-0.646411,"eighty":-0.251439,"marketCap":3564160},{"date":"2024-10-11","current":-0.907513,"twenty":-2.454308,"median":-0.732285,"eighty":-0.251439,"marketCap":3339292},{"date":"2024-10-18","current":-1.635766,"twenty":-2.442905,"median":-0.803263,"eighty":-0.251801,"marketCap":6018976},{"date":"2024-10-25","current":-1.641201,"twenty":-2.426585,"median":-0.838697,"eighty":-0.253271,"marketCap":6038973},{"date":"2024-11-01","current":-1.543381,"twenty":-2.400017,"median":-0.855568,"eighty":-0.253525,"marketCap":5679034},{"date":"2024-11-08","current":-1.272877,"twenty":-2.391625,"median":-0.858624,"eighty":-0.254478,"marketCap":5379085},{"date":"2024-11-15","current":-1.109627,"twenty":-2.378629,"median":-0.863207,"eighty":-0.255552,"marketCap":4689202},{"date":"2024-11-22","current":-1.116724,"twenty":-2.37082,"median":-0.867791,"eighty":-0.255564,"marketCap":4719197},{"date":"2024-11-29","current":-1.353319,"twenty":-2.350561,"median":-0.867791,"eighty":-0.255614,"marketCap":5719027},{"date":"2024-12-06","current":-1.580449,"twenty":-2.350518,"median":-0.876957,"eighty":-0.257087,"marketCap":6678864},{"date":"2024-12-13","current":-1.301268,"twenty":-2.310387,"median":-0.883068,"eighty":-0.257854,"marketCap":5499065},{"date":"2024-12-20","current":-1.315463,"twenty":-2.307556,"median":-0.89142,"eighty":-0.25795,"marketCap":5559054},{"date":"2024-12-27","current":-1.447956,"twenty":-2.300648,"median":-0.895291,"eighty":-0.258031,"marketCap":6118959},{"date":"2025-01-03","current":-1.637232,"twenty":-2.270313,"median":-0.899874,"eighty":-0.26035,"marketCap":6918823},{"date":"2025-01-10","current":-1.386442,"twenty":-2.245088,"median":-0.908323,"eighty":-0.262114,"marketCap":5859003},{"date":"2025-01-17","current":-1.371584,"twenty":-2.20758,"median":-0.910569,"eighty":-0.264263,"marketCap":5796214},{"date":"2025-01-24","current":-1.358051,"twenty":-2.159893,"median":-0.913624,"eighty":-0.266969,"marketCap":5739024},{"date":"2025-01-31","current":-1.350385,"twenty":-2.138342,"median":-0.919736,"eighty":-0.267005,"marketCap":5706629},{"date":"2025-02-07","current":-1.182971,"twenty":-2.135395,"median":-0.922791,"eighty":-0.267175,"marketCap":4999150},{"date":"2025-02-14","current":-1.187703,"twenty":-2.118387,"median":-0.925408,"eighty":-0.267696,"marketCap":5019146},{"date":"2025-02-21","current":-1.159312,"twenty":-2.067579,"median":-0.933486,"eighty":-0.267926,"marketCap":4899167},{"date":"2025-02-28","current":-1.083601,"twenty":-2.053291,"median":-0.939661,"eighty":-0.268118,"marketCap":4579221},{"date":"2025-03-07","current":-1.13092,"twenty":-2.046154,"median":-0.954875,"eighty":-0.268406,"marketCap":4779187},{"date":"2025-03-14","current":-0.913253,"twenty":-2.038923,"median":-0.96557,"eighty":-0.268406,"marketCap":3859343},{"date":"2025-03-21","current":-1.078869,"twenty":-2.030531,"median":-0.973224,"eighty":-0.269039,"marketCap":4559224},{"date":"2025-03-28","current":-0.946377,"twenty":-2.018529,"median":-0.977792,"eighty":-0.270157,"marketCap":3999320},{"date":"2025-04-04","current":-1.111863,"twenty":-2.007547,"median":-0.993696,"eighty":-0.274258,"marketCap":5708433},{"date":"2025-04-11","current":-0.963142,"twenty":-1.996559,"median":-0.993696,"eighty":-0.277231,"marketCap":4944885},{"date":"2025-04-17","current":-0.885241,"twenty":-1.986198,"median":-0.977792,"eighty":-0.277999,"marketCap":4544931},{"date":"2025-04-25","current":-1.069371,"twenty":-1.973809,"median":-0.985744,"eighty":-0.278191,"marketCap":5490276},{"date":"2025-05-02","current":-0.970224,"twenty":-1.965861,"median":-0.984388,"eighty":-0.278543,"marketCap":4981244},{"date":"2025-05-09","current":-0.885241,"twenty":-1.961438,"median":-0.976037,"eighty":-0.280047,"marketCap":4544931},{"date":"2025-05-16","current":-1.084259,"twenty":-1.95456,"median":-0.974768,"eighty":-0.285806,"marketCap":5453917},{"date":"2025-05-23","current":-1.011975,"twenty":-1.939285,"median":-0.98109,"eighty":-0.287638,"marketCap":5090323},{"date":"2025-05-30","current":-1.040889,"twenty":-1.935399,"median":-0.989042,"eighty":-0.288484,"marketCap":5235760},{"date":"2025-06-06","current":-1.069802,"twenty":-1.927469,"median":-0.998427,"eighty":-0.289862,"marketCap":5381198},{"date":"2025-06-13","current":-1.440125,"twenty":-1.914401,"median":-1.003159,"eighty":-0.294928,"marketCap":7243952},{"date":"2025-06-20","current":-1.335965,"twenty":-1.909079,"median":-1.007891,"eighty":-0.305874,"marketCap":6720018},{"date":"2025-06-27","current":-1.331436,"twenty":-1.908333,"median":-1.011975,"eighty":-0.333739,"marketCap":6697239},{"date":"2025-07-03","current":-1.403895,"twenty":-1.904922,"median":-1.01215,"eighty":-0.359501,"marketCap":7061714},{"date":"2025-07-11","current":-1.444654,"twenty":-1.894982,"median":-1.015035,"eighty":-0.368334,"marketCap":7266732},{"date":"2025-07-18","current":-1.449182,"twenty":-1.89151,"median":-1.02057,"eighty":-0.37388,"marketCap":7289512},{"date":"2025-07-25","current":-1.403895,"twenty":-1.879835,"median":-1.028991,"eighty":-0.37827,"marketCap":7061714},{"date":"2025-08-01","current":-1.304264,"twenty":-1.838255,"median":-1.03366,"eighty":-0.389701,"marketCap":6560560},{"date":"2025-08-08","current":-1.268035,"twenty":-1.832254,"median":-1.040889,"eighty":-0.392331,"marketCap":6378323},{"date":"2025-08-15","current":-1.090834,"twenty":-1.82078,"median":-1.041044,"eighty":-0.400949,"marketCap":6879476},{"date":"2025-08-22","current":-1.025817,"twenty":-1.817936,"median":-1.040967,"eighty":-0.403885,"marketCap":6469441},{"date":"2025-08-25","current":-1.011369,"twenty":-1.816289,"median":-1.040889,"eighty":-0.404918,"marketCap":6378323}],"updateTime":1756231997033},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBFM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559625429","title":"Sunshine Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559625429","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559625429?lang=en_us&edition=fundamental","pubTime":"2025-08-15 05:01","pubTimestamp":1755205273,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma Inc reports results for the quarter ended June 30 - Earnings SummarySunshine Biopharma Inc SBFM.OQ reported a quarterly adjusted loss of 39 cents per share for the quarter ended Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nL8N3U61P4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBFM"],"gpt_icon":0},{"id":"2559462411","title":"Sunshine Biopharma Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2559462411","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559462411?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:59","pubTimestamp":1755032359,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma Inc  expected to post a loss of11cents a share - Earnings Preview Sunshine Biopharma Inc SBFM.OQ SBFM.O is expected to  show a rise in quarterly revenue when it reports  results on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U41ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBFM"],"gpt_icon":0},{"id":"2542849395","title":"Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2542849395","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542849395?lang=en_us&edition=fundamental","pubTime":"2025-06-11 20:30","pubTimestamp":1749645037,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma Inc.'s wholly owned Canadian subsidiary, Nora Pharma Inc., has introduced Gabapentin, a new generic anticonvulsant medication, to the Canadian market. This launch signifies a strategic move to expand their presence in Canada's thriving $9.4 billion generic drugs market. Gabapentin, a generic version of Neurontin, is utilized for treating neuropathic pain and epilepsy, as well as conditions like diabetic neuropathy, central pain, and postherpetic neuralgia. Nora Pharma's Gabapentin is available in capsule form in strengths of 100 mg, 300 mg, and 400 mg, catering to both children and the elderly due to ease of administration. This initiative aligns with the broader growth of the global Gabapentin market, projected to reach $3.07 billion by 2030, driven by factors such as the increasing prevalence of neurological disorders and a shift away from opioid use for pain management.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL5CJDD3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SBFM"],"gpt_icon":0},{"id":"2536063003","title":"Sunshine Biopharma Inc. Reports 18% Revenue Increase in Q1 2025, Net Loss Narrows to $1.18 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2536063003","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536063003?lang=en_us&edition=fundamental","pubTime":"2025-05-20 05:06","pubTimestamp":1747688811,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma Inc. has released its first-quarter results for 2025, reporting an 18% increase in revenues compared to the same period last year. The company's revenues reached $8.9 million, up from $7.54 million in the first quarter of 2024. Despite the revenue growth, Sunshine Biopharma Inc. reported a net loss of $1.18 million, a slight improvement from the $1.28 million net loss reported in the first quarter of the previous year. In addition to the financial results, Sunshine Biopharma appointed a new Chief Commercial Officer, Mr. Michel Roy, and launched six new generic prescription drugs. These include two antibiotics, two drugs for gastrointestinal disorders, and two drugs for schizophrenia. The company also completed additional studies on orthotopic human tumor models in mice, further confirming its K1.1 mRNA Lipid Nanoparticle product as a novel therapeutic agent for human hepatocellular carcinoma. Sunshine Biopharma's CEO, Dr. Steve Slilaty, emphasized the company's commi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL6shqVN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBFM"],"gpt_icon":0},{"id":"2535453803","title":"Sunshine Biopharma Q1 EPS $(0.44) Up From $(2.00) YoY, Sales $8.90M Up From $7.54M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535453803","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535453803?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:53","pubTimestamp":1747342401,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma Q1 EPS $(0.44) Up From $(2.00) YoY, Sales $8.90M Up From $7.54M YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45454639/sunshine-biopharma-q1-eps-0-44-up-from-2-00-yoy-sales-8-90m-up-from-7-54m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00509","SBFM"],"gpt_icon":0},{"id":"2529801447","title":"Sunshine Biopharma Unit Rolls Out Afinitor Alternative Everolimus in Canadian Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2529801447","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529801447?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:20","pubTimestamp":1745241606,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma  said Monday its Canadian unit Nora Pharma has launched a generic version of Everolimus in Canada.The company said the drug is a substitute for Afinitor and is used to treat certain types of cancer, including advanced kidney cancer, certain breast cancers, and specific neuroendocrine tumors.The product is available in 2.5 mg, 5 mg, and 10 mg tablet doses, Sunshine said.Shares of the company were up more than 16% in recent Monday premarket activity.Price: 1.46, Change: +0.21, Percent Change: +16.84","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00509","SBFM","BK4139","BK1113","BK1543"],"gpt_icon":0},{"id":"2529980908","title":"Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2529980908","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529980908?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238600,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Everolimus in the Canadian generic prescription drugs market.Everolimus is a generic equivalent of the brand name Afinitor. Everolimus is indicated for the treatment of  advanced renal cell carcinoma,  breast cancer in post-menopausal women with advanced HER2-negative genotype,  progressive well or moderately differentiated neuroendocrine tumors of pancreatic, gastrointestinal or lung origin, and  subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Nora Pharma's Everolimus is available in strengths of 2.5 mg, 5 mg, and 10 mg and comes in blister packs of 30 tablets.According to DATAINTELO, the global Everolimus market was valued at $2.5 billion in 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-launches-everolimus-canada-123000090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAGR","SBFM","BK4159","BK4139","SBFMW"],"gpt_icon":0},{"id":"2524726228","title":"Sunshine Biopharma Closes $2.5 Million Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2524726228","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524726228?lang=en_us&edition=fundamental","pubTime":"2025-04-03 23:22","pubTimestamp":1743693734,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma  said Thursday it has raised about $2.5 million following the close of its registered direct offering of shares and pre-funded warrants to institutional investors.The company said it will use the proceeds for general corporate purposes and working capital. Aegis Capital Corp. was the placement agent for the offering.Price: 2.01, Change: -0.24, Percent Change: -10.76","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SBFM","BK1113","BK1543","00509"],"gpt_icon":0},{"id":"2524414033","title":"Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2524414033","media":"ACCESS Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524414033?lang=en_us&edition=fundamental","pubTime":"2025-04-03 01:20","pubTimestamp":1743614400,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc.  , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $2.46 million of shares of Common Stock and pre-funded warrants at a price of $2.07 per share of Common Stock. The entire transaction has been priced at the market under Nasdaq rules.The offering consisted of the sale of 1,188,404 shares of Common Stock . The offering price per Common Share is $2.07 . The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full.This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-inc-announces-2-172000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","BK4112","SQQQ","MNQmain","IE00BKPKM429.USD","LU2210149790.SGD","USAW.SI","SBFMW","TQQQ","USJW.SI","BK4139","QID","SBFM","LU2210150020.SGD",".IXIC","LU2095319765.USD","TSYW.SI","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","NQmain","QLD","NVIW.SI","BK4588","PSQ","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2524413515","title":"Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2524413515","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524413515?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:35","pubTimestamp":1743608114,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma&#39;s K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44609792/nano-cap-sunshine-biopharma-stock-shoots-higher-on-encouraging-preclinical-data-from-potential-mrna-based-liver-cancer-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1543","BK4139","SBFM","HCC","00509","BK4006","BK1113"],"gpt_icon":0},{"id":"2524957524","title":"Wall Street Awaits Trump's Tariff Plans as US Equity Futures Drop Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2524957524","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524957524?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:07","pubTimestamp":1743599239,"startTime":"0","endTime":"0","summary":"US equity futures fell ahead of Wednesday's opening bell as investors awaited President Donald Trump's tariff policy announcement.Dow Jones Industrial Average futures were down 0.7%, S&P 500 futures d","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","NQmain","BK4547","BK4077","DOG",".IXIC","DDM","DJT","UDOW","BK4215","PSQ","USAW.SI","QLD","QID","SDOW","DXD","TRUMP.USD.CC","TSYW.SI","USJW.SI",".SPX",".DJI","BK4139","MNQmain","NVIW.SI","SBFM","SQQQ","NCNO","DJX","BK4023","TQQQ","BK4585","BK4516","EQR"],"gpt_icon":1},{"id":"2524493428","title":"Sunshine Biopharma Completes Additional Studies of mRNA Therapy for Liver Cancer; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2524493428","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524493428?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:51","pubTimestamp":1743598287,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma  said Wednesday that it completed additional studies of its K1.1 mRNA lipid nanoparticle product, which confirmed it as a novel therapeutic agent for liver cancer.Under repeated dosing, the mRNA product was found to reduce the growth of three different types of human hepatocellular carcinoma tumors in mice, with good tolerability, the company said.The company said it is now conducting additional studies to define the optimum dosing of truncated version of the product, which is said to offer better efficacy at lower doses.Sunshine Biopharma shares were 49% higher in recent premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00509","SBFM","BK1113","BK1543","BK4139"],"gpt_icon":0},{"id":"2524493344","title":"Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2524493344","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524493344?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:00","pubTimestamp":1743595200,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc.  , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle  product as a novel therapeutic agent for human hepatocellular carcinoma.Human hepatocellular carcinoma  is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several treatment options were made available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%.About Sunshine Biopharma Inc.Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-announces-positive-results-120000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SBFMW","HCC","BK4139","SBFM","BK4006"],"gpt_icon":0},{"id":"2524461776","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2524461776","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524461776?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:37","pubTimestamp":1743593860,"startTime":"0","endTime":"0","summary":"SHF Holdings  shares surged 58% pre-bell Wednesday following a 2.3% loss in the previous session.Design Therapeutics  shares jumped 52%, reversing Tuesday's loss.Sunshine Biopharma  shares advanced 55%, a day after the company reported higher annual revenue for its fiscal 2024.TTEC Holdings  shares were up 28% in recent premarket activity Wednesday. The company said late Tuesday that its special board committee concluded its review of Chief Executive Kenneth Tuchman's unsolicited buyout offer for TTEC and suggested to engage with him for a definitive deal proposal.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHFS","DSGN","BK4106","TTEC","SBFM","BK4505","BK4164","BK4539","BK4139","BK4226"],"gpt_icon":0},{"id":"2524242631","title":"Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2524242631","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524242631?lang=en_us&edition=fundamental","pubTime":"2025-04-02 05:22","pubTimestamp":1743542555,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44596781/sunshine-biopharma-2024-revenue-34-9m-up-from-24-1m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00509","SBFM"],"gpt_icon":0},{"id":"2524122965","title":"Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2524122965","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524122965?lang=en_us&edition=fundamental","pubTime":"2025-04-02 05:09","pubTimestamp":1743541740,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc.  , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 annual report on Form 10-K on Tuesday, April 1, 2025. The following are highlights of the report:. Revenue in 2024 grew to $34.9 million, a 45% increase over 2023 revenue of $24.1 million.Completed an underwritten public offering of approximately $10 million in gross proceeds for expansion of sales operations.Launched 13 new generic prescription drugs, 4 under cross-licensing agreements and 9 under distribution agreements.Announced publication of groundbreaking research results in the Journal of Medicinal Chemistry  demonstrating the superior efficacy of Sunshine Biopharma's new Coronavirus PLpro inhibitor. The study showcases a PLpro inhibitor with sub-micromolar potency and robust in vivo efficacy in a mouse model of SARS-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-reports-revenue-34-210900864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SBFMW","SBFM"],"gpt_icon":0},{"id":"2523937680","title":"Sunshine Biopharma Inc  expected to post earnings of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523937680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523937680?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:07","pubTimestamp":1743192426,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma Inc  expected to post earnings of11cents a share - Earnings Preview Sunshine Biopharma Inc SBFM.OQ SBFM.O is expected to show a rise in quarterly revenue when it reports  results on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB1QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBFM"],"gpt_icon":0},{"id":"2522071076","title":"Sunshine Biopharma signs agreement for rights to market two generic antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522071076","media":"TipRanks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522071076?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:06","pubTimestamp":1742908002,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma  announced that is has signed a strategic agreement granting it the rights to market two new generic antibiotics in Canada. The Company anticipates launching these new products through its wholly-owned Canadian subsidiary, Nora Pharma, in the next six to nine months following regulatory approval.Discover stocks' market position with detailed  competitor analyses.Read More on SBFM:Questions or Comments about the article?Sunshine Biopharma in strategic deal for new generic antibiotics in Canada. Sunshine Biopharma’s Nora Pharma acquires gastrointestinal drug rights","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/sunshine-biopharma-signs-agreement-rights-130642219.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-signs-agreement-rights-130642219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SBFM","SBFMW","BK4139"],"gpt_icon":0},{"id":"2522075017","title":"Sunshine Biopharma Inc  expected to post earnings of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075017?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:06","pubTimestamp":1742846769,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma Inc  expected to post earnings of11cents a share - Earnings Preview Sunshine Biopharma Inc SBFM.OQ SBFM.O is expected to show a rise in quarterly revenue when it reports  results on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL5N3Q71TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBFM"],"gpt_icon":0},{"id":"2518270032","title":"Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270032","media":"ACCESS Newswire","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270032?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:00","pubTimestamp":1741611600,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months.Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 15 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG, a biosimilar of NEULASTA. Like NEULASTA, NIOPEG is a long-acting form of recombinant human granulocyte colony-stimulating factor . It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-acquires-rights-launch-130000578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SBFM","BK4159","BK4139","CAGR","SBFMW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}